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Abstract
Background: Alzheimer’s disease (AD) is a neurodegenerative disorder, primarily affecting memory. That disorder is
thought to be a consequence of neuronal network disturbances and synapse loss. Decline in cognitive function is
associated with a high burden of neuropsychiatric symptoms (NPSs) such as depression. The cyclic nucleotides
cyclic adenosine-3',5'-monophosphate (cAMP) and cyclic guanosine-3',5'-monophosphate (cGMP) are essential
second messengers that play a crucial role in memory processing as well as synaptic plasticity and are potential
therapeutic targets. Biomarkers that are able to monitor potential treatment effects and that reflect the underlying
pathology are of crucial interest.
Methods: In this study, we measured cGMP and cAMP in cerebrospinal fluid (CSF) in a cohort of 133 subjects
including 68 AD patients and 65 control subjects. To address the association with disease progression we correlated
cognitive status with cyclic nucleotide levels. Because a high burden of NPSs is associated with decrease in cognitive
function, we performed an exhaustive evaluation of AD-relevant marker combinations in a depressive subgroup.
Results: We show that cGMP, but not cAMP, levels in the CSF of AD patients are significantly reduced compared with
the control group. Reduced cGMP levels in AD patients correlate with memory impairment based on Mini-Mental State
Examination score (r = 0.17, p = 0.048) and tau as a marker of neurodegeneration (r = –0.28, p = 0.001). Moreover, we
were able to show that AD patients suffering from current depression show reduced cGMP levels (p = 0.07) and exhibit
a higher degree of cognitive impairment than non-depressed AD patients.
Conclusion: These results provide further evidence for an involvement of cGMP in AD pathogenesis and accompanying
co-morbidities, and may contribute to elucidating synaptic plasticity alterations during disease progression.
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Background
The cyclic nucleotides cyclic adenosine-3′,5′-monopho-
sphate (cAMP) and cyclic guanosine-3′,5′-monophosphate
(cGMP) are essential second messengers and play a crucial
role in memory processing and synaptic plasticity. Both
cAMP and cGMP are important elements in intracellular
signal transduction cascades, mediating effects mainly by
activating protein kinases (PKA and PKG) and ion channels
[1]. Activation of these cascades leads to phosphorylation of
the synaptic plasticity-related transcription factor cAMP-
response element binding protein (CREB) [2]. CREB activa-
tion by phosphorylation at Ser133 has been shown to be
necessary for strengthening synaptic plasticity and long-
term memory formation [3]. Intracellular cAMP/cGMP
levels are tightly regulated by synthesis from adenosine 5′-
triphosphate/guanosine 5′-triphosphate via adenylyl/guany-
lyl cyclases and degradation via phosphodiesterases (PDEs),
which catalyses the hydrolysis of the cyclic nucleotides to
the corresponding 5′-monophosphates [1]. Alzheimer’s dis-
ease (AD) is a neurodegenerative disorder, affecting mem-
ory encoding and storage-related brain regions such as the
hippocampus and cortical areas [4]. AD is histochemically
defined by Aβ plaques and neurofibrillary tangles consisting
of tau [5]. Soluble Aβ aggregates seem to affect hippocam-
pal synaptic plasticity, and affect synapse and memory loss
via CREB signalling [6]. Since the early 1990s, the interest
in cGMP modulating PDEs has increased remarkably, as
the number of PDE inhibitors in clinical trials for the treat-
ment of several vascular as well as neurological disorders
has grown considerably [7]. In fact, mice treated with PDE9
inhibitors (cGMP specific) exhibit improved learning and
memory [8], and inhibition of PDE9A further leads to a res-
cue of Aβ-induced deficits in synaptic plasticity and cogni-
tion in the APP transgenic mouse model tg2576 [9].
Changes in cyclic nucleotide signalling due to altered PDE
expression in AD patients may therefore lead to an altered
level of CREB-induced neuroprotection [10].
Given that AD is characterized by a progressive loss of
synapses leading to dementia, cyclic nucleotides could
serve as promising biomarkers because synaptic function is
closely modulated by cGMP signalling, which seems to be
reduced in the brains of AD patients [11]. Thus, selective
inhibition of PDEs could offer novel approaches in the
therapy of people suffering from dementia. To monitor
therapy and to determine disease development and pro-
gression, one focus in biomedical research of neurodegen-
erative diseases is the identification of novel biomarkers
[12, 13]. Further, because the CSF compartment is close to
the neuropathological changes due to AD, this makes it the
preferred body fluid for identifying novel biomarkers for
brain-related diseases. A recent study reported that the de-
creased levels of cGMP in the CSF of AD patients are asso-
ciated with cognitive decline and amyloid pathology [14].
However, another study reported an increase in cAMP, but
not in cGMP, levels in the CSF of AD patients [15]. Both
studies were limited in terms of cohort size (n = 79
and n = 20 respectively).
Although cognitive function is primarily known to be
impaired in AD patients, there is evidence that extensive
neuronal connections exist between the neural regions
of cognition/memory (hippocampus) and emotions
(amygdala) [16, 17]. This relationship is in line with a
recent study showing a high prevalence of late-life de-
pressive symptoms in dementia [18]. In addition, there is
strong evidence that the glutamatergic system, including
cGMP signalling, is involved in the neuropathology of
depressive symptoms in AD [19, 20].
To further elucidate the role of cyclic nucleotides in AD
and accompanying neuropsychiatric symptoms (NPSs)
such as cognitive decline and depression, we measured
the cGMP and cAMP levels in the CSF in a large cohort
comprised of 68 AD patients and 65 non-demented con-
trol subjects. We evaluated whether cAMP/cGMP levels
correlate with disease parameters such as cognitive func-
tion based on Mini-Mental State Examination (MMSE)
score and current depression based on the Beck Depres-
sion Inventory (BDI). The diagnostic power of these
parameters was also determined. This article confirms the
involvement of cGMP in AD progression in a highly se-
lective cohort and reveals—to the best of our knowledge
for the first time—a connection between CSF cGMP and
late-life depressive symptoms in AD patients.
Methods
Participants
Patient cohorts were recruited between 2003 and 2015 at the
Memory Clinic of the Neurology University Hospital in Ulm,
Germany. CSF was collected by lumbar puncture at the same
institute. All participants underwent a comprehensive clinical
neurological examination and a detailed neuropsychological
assessment including the MMSE as a general screening test
[21] and the BDI and Geriatric Depression Scale (GDS) as
tests for current depression. ApoE ε allele status was also de-
termined. Exclusion criteria were a history of stroke or any
other reason for cognitive impairment, other neurodegenera-
tive diseases, a history of alcohol or drug abuse, visual or lin-
guistic impairment and cephalalgia. The diagnostic criteria
were defined according to the NIA–AA criteria [22–24],
which use a combination of clinical diagnosis and the CSF
biomarker profile including Aβ1–42 and T‐tau. Only patients
fulfilling the diagnostic criteria for “probable” AD were
included. Inclusion criteria were CSF tau > 350 pmol/ml, CSF
Aβ < 650 pmol/ml and MMSE score≤ 25. Unrelated control
subjects were recruited at the same site.
Control subjects
The group of controls comprised 65 cognitively normal
individuals (37 male and 28 female) who presented at the
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memory clinic with normal CSF core biomarkers (CSF
tau < 350 pmol/ml, CSF Aβ > 650 pmol/ml, MMSE score ≥
25) with a median (IQR) age of 59 (54–71) years. The
control group showed no evidence of stroke, (history of)
headache or neuroinflammatory or other neurodegenera-
tive diseases according to the evaluation of a neurologist.
The diagnosis of current depression was made by
applying BDI (cut-off value ≥ 13) or GDS (cut-off value ≥
5). The second inclusion criterion was administration of
antidepressants. Twenty-five of the AD patients suffered
from depression.
Demographic details of all patients are presented in
Table 1.
Standard protocol approvals, registrations and patient
consent
The study was approved by the university ethics board
(No. 2001/67). All individuals gave written informed
consent to their participation in the study.
Measurement of CSF β-amyloid(42) and tau levels
CSF collection and pre-analytic processing were per-
formed using a standardized protocol as described previ-
ously [25]. Briefly, CSF samples were collected in
propylene tubes after lumbar puncture and centrifuged
immediately after collection. Samples were stored at –
80 °C in Eppendorf tubes within 2 h until further ana-
lysis. Standard sandwich ELISA techniques were used to
quantify the CSF levels of β-amyloid(42) (Innotest β-
amyloid 1–42) [26] and t-tau (Innotest hTau-Ag) [27]
following the manufacturer’s instructions.
Enzyme-linked immunosorbent assay
CSF levels of cAMP and cGMP were determined by
ELISA. Both cAMP and cGMP ELISAs were obtained
from Enzo Lifesciences (cAMP: #ADI-900-066; cGMP:
#ADI-900-014) and used according to the manufacturer’s
protocol. Briefly, for cAMP, 100 μl standard or CSF and
100 μl 0.1 M HCl were added into the appropriate wells.
For cGMP, 200 μl CSF and 200 μl 0.1 M HCl were used.
After adding 50 μl of the conjugate and 50 μl of the anti-
body to the appropriate wells, the plates were incubated at
room temperature for 2 h with shaking. After washing
steps, pNpp substrate and stop solution were added and
the optical density was measured at 405 nm. The assays
were blind for patient identification and disease status.
Statistics
Statistical analyses were carried out with GraphPad Prism
version 6.05. Compared groups were tested for normality
(Kolmogorov–Smirnov test) and failed. Groups were com-
pared by Mann–Whitney U rank-sum test or Kruskal–
Wallis test when more than two groups were compared.
Correlation of parameters was calculated using Spear-
man’s rank correlation coefficient. p < 0.05 was considered
statistically significant. The results are expressed as me-
dian (25th–75th percentile).
Classification experiments were performed using R
Version 3.3.0 [28] and the TunePareto R package [29]. We
analysed the predictive performance of combinations of
markers in an AD vs control scenario on a subgroup of
patients with depression. The utilized classes consisted of
19 AD samples and 33 control samples, all with depres-
sion. Seven parameters were used for the experiments:
total protein, albumin, ApoE4 status, cGMP, cAMP, age
and thyroid problems. The predictive performance of all
combinations (n = 27 – 1 = 127) was determined in a
cross-validation experiment (10 × 10 folds) for each par-
ameter combination. In this experiment the data set is
split into 10 folds of approximately equal size. Nine folds
are used for training a model, and the remaining fold is
used for testing the model. This is repeated until each fold
has been used once as test fold. To exclude any influence
of the sample order, 10 repetitions have been performed
using random permutations of the samples. A classifica-
tion tree (CART) based on the Gini index was utilized as
a base classifier [30]. As a performance measure, the mean
of sensitivity and specificity was used because classes are
not balanced.
Results
CSF levels of cGMP, but not cAMP, are decreased in AD
patients
The ELISA analysis of cGMP and cAMP levels in the
CSF of AD patients revealed a significant reduction of
about 40% in cGMP levels (p = 0.017; Fig. 1a). The
median concentration was 1.23 (0.43–3.84) pmol/ml
(control) vs 0.75 (0.09–2.01) pmol/ml (AD). cAMP levels
were not altered in the CSF of AD patients compared
with the controls (Fig. 1b) (7.51 pmol/ml vs 6.51 pmol/
ml, n.s.) (AD).













Tau (pg/ml) 229.5 (172.25–292) 907 (641.5–1100.5) <0.01
Aβ42 (pg/ml) 1012.5 (850.75–1177.25) 493 (390.5–556) <0.01
MMSE score 29 (27–30) 20 (16–23) <0.01
Data presented as median (interquartile range) unless otherwise stated.
p values calculated using the Mann–Whitney test, AD vs control
AD Alzheimer’s disease, MMSE Mini-Mental State Examination
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Reduction in cGMP levels in CSF of AD patients correlates
with lower MMSE score and negatively correlates with
CSF tau
Because cGMP is closely related to memory function we
next examined the correlation between CSF cGMP levels
and the cognitive performance of all participants (MMSE
score). A statistically significant correlation was observed
(r = 0.17, p = 0.046; Table 2, Fig. 2a). To obtain more de-
tailed information about the relationship between cGMP
levels and severity of dementia, AD patients were stratified
by their MMSE scores into three groups (severe AD,
moderate AD, mild AD). The first tertile comprises AD
patients with an MMSE score of 5–17 (severe AD; n = 23),
the second tertile patients with an MMSE score of 17–23
(moderate AD; n = 23) and the third tertile comprises AD
patients with an MMSE score of 23–27 (mild AD; n = 22).
We observed a trend of reduction in mild dementia
(~10%) and in moderate dementia (~40%). The compari-
son of severe dementia with the lowest MMSE scores
showed a significant decrease in cGMP levels of about
50% compared with the controls (p < 0.05; Fig. 2b). The
median concentration was 1.23 (0.43–3.84) pmol/ml
(control), 1.08 (0.08–2.78) pmol/ml (severe AD), 0.72
(0.08–2.12) pmol/ml (moderate AD) and 0.69 (0.16–1.45)
pmol/ml (mild AD). Furthermore, the decrease in CSF
cGMP negatively correlates significantly with CSF tau
levels (r = 0.28, p = 0.001; Table 2, Fig. 2c).
Capability of cGMP in CSF as a biomarker of AD
To test the capability of cGMP as a potential biomarker of
AD we calculated the receiver operating characteristic
(ROC) curve. The ROC curve is depicted in Fig. 3. Accord-
ing to ROC curve analysis, the CSF levels of cGMP discrim-
inate the AD patients from control subjects with a
specificity of 86.15% and a sensitivity of 37.68% (AUC=
0.62, 95% CI: 0.52–0.71, p= 0.017). The cut-off value was
calculated using Youden’s index and the likelihood ratio.
The cut-off value for the calculated specificity and sensitivity
was <0.201 pmol/ml.
Reduced cGMP levels in AD patients with current
depression
To test the question of whether depression as the most
common early sign of NPSs affects cGMP levels in AD
patients, we subgrouped the AD patients by diagnosis of
current depression and compared them with non-
depressed AD patients. To exclude that the intake of anti-
depressants alone confounds the measurements of cyclic
nucleotide levels, we first tested whether subjects receiv-
ing antidepressants show altered cAMP or cGMP levels
compared with non-recipients. We did not see a statisti-
cally significant difference (Additional file 1: Figure S1). In
contrast, we observed that CSF cGMP levels are reduced
(~73%, p = 0.07) in AD patients suffering from current
depression compared with non-depressed AD patients
(Fig. 4a). The median of concentrations was 0.20 (0.08–
1.6) pmol/ml (current depression) and 0.73 (0.10–2.00)
pmol/ml (non-depression).
Our analyses further revealed that there is a statistically
significant reduction in MMSE scores for AD patients
Fig. 1 cGMP, but not cAMP, levels in CSF of AD patients are reduced. Box plots comparing CSF levels of cGMP (a) and cAMP (b) in CSF of
patients with AD compared with control patients measured by ELISA. (a) cGMP levels in the CSF of AD patients were significantly reduced
compared with control subjects (p = 0.017). (b) cAMP levels in the CSF of AD patients were not altered. Mann–Whitney U test. AD Alzheimer’s
disease, cAMP cyclic adenosine-3',5'-monophosphate, cGMP cyclic guanosine-3',5'-monophosphate, CSF cerebrospinal fluid
Table 2 Correlations between CSF cyclic nucleotide levels and
clinical and pathological markers of AD
CSF cGMP CSF cAMP
rs p rs p
CSF Aβ42 0.15 0.09 0.056 0.5183
CSF tau –0.28 0.001 –0.067 0.438
MMSE score 0.17 0.046 –0.047 0.59
Correlation coefficients (rs) and p values calculated using Spearman’s rank
correlation analysis. Statistically significant results depicted in bold
AD Alzheimer’s disease, cAMP cyclic adenosine-3',5'-monophosphate, cGMP
cyclic guanosine-3',5'-monophosphate, CSF cerebrospinal fluid, MMSE
mini-mental state examination
Hesse et al. Alzheimer's Research & Therapy  (2017) 9:17 Page 4 of 11
suffering from current depression compared with non-
depressed AD patients (~10%; p = 0.03) (Fig. 4b).
For the subgroup of samples with depression, all
combinations of the biomarkers total protein, albumin,
ApoE4 status, cGMP, cAMP, age and thyroid problems
were tested for their predictive performance (AD vs con-
trol). Fig. 5 shows that accuracies of up to 81.5% were
reached (biomarker combination: “cGMP”, “AgeAtLP”,
“Albumin”). By looking at all combinations it can be
seen that cGMP is an important component because it
is part of all top-performing models with an accur-
acy > 70% (19 models).
Discussion
The loss of synapses in memory-related brain areas is a
very early event in the disease process of AD and the
strongest structural correlate with the decrease in cogni-
tive performance of patients [31, 32]. Synaptic plasticity
is a crucial characteristic of neurons that is thought to
underlie memory and learning [33–35]. One important
regulator of synaptic plasticity is the signalling of cyclic
nucleotides [36, 37], which is in turn impaired in the
CNS of AD patients [38–42]. CREB, the common down-
stream target of both cAMP and cGMP signalling and
regulator of structural correlates of cognition, is also af-
fected in AD brains [6, 43, 44]. Because of the fact that
pathological processes of AD start before the onset of
clinical manifestations [45–47], the identification of
novel biomarkers is of crucial interest. Up to now only
two studies have been performed analysing the levels of
the cyclic nucleotides cAMP and cGMP in the CSF of
patients suffering from AD [14, 15]. The inconsistency
in results may be due to limited cohort sizes (n = 20
[15]; n = 79 [14]) and different study designs. Thus, in
the present study we investigated the concentrations of
the cyclic nucleotides cAMP and cGMP in the CSF of a
well-characterized larger cohort of AD patients and
compared them with non-AD controls.
As a main activator of CREB, a decrease in cAMP
signalling has been reported in the hippocampus and
temporal cortex of AD patients [48, 49]. In these studies
cAMP levels were not determined directly. Yamamoto
et al. [48] determined the hippocampal levels of the neural
specific adenylyl cyclase type I (cAMP synthesis) and
found these to be decreased in AD cases. Another study
conducted by Kim et al. [49] revealed that PKA (specific
downstream target of cAMP) levels are lower in AD corti-
ces. Regarding PDE expression in AD brains, the severest
clinical stages are associated with an increase in PDE8B
Fig. 2 Only severely demented AD patients show a significant decrease in CSF levels of cGMP. a Correlation analysis of CSF cGMP levels with the
cognitive performance (MMSE score) of all participants showed a significant correlation of CSF cGMP levels and MMSE scores (p = 0.046, Spearman’s
rank correlation coefficient). b CSF levels of cGMP of control subjects and AD patients stratified by their MMSE scores (severe AD =MMSE 5–17,
moderate AD =MMSE 17–23, mild AD =MMSE 23–27). Only severely demented AD patients show a significant reduction in CSF cGMP levels
compared with the control group (p < 0.01, Mann–Whitney U test). c Correlation of CSF cGMP levels with neurodegeneration marker tau showed a
significantly negative correlation (p = 0.001, Spearman’s rank correlation coefficient). cGMP cyclic guanosine-3',5'-monophosphate, MMSE mini-mental
state examination
Fig. 3 Diagnostic potential of cGMP as an AD biomarker. ROC curve
analysis of CSF levels of cGMP in AD patients compared with control
subjects. Sensitivity is defined as the fraction of those with the
disease correctly identified as positive by the test. Specificity is
defined as the fraction of those without the disease correctly
identified as negative by the test. Youden’s index = sensitivity +
specificity – 1. Likelihood ratio = sensitivity / (1 – specificity).
Cut-off value for cGMP was <0.201 pmol/ml. AUC area under the
curve, CI 95% confidence interval
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expression in memory-associated brain regions, such as
the entorhinal cortex [50]. Additionally, chronic inhibition
of PDE4D (cAMP specific) led to improved spatial mem-
ory function in APPswe/PS1dE9 mice [51]. Demonstrating
altered levels of cAMP synthesizing/degrading enzymes in
AD brains, these studies provide further evidence for a re-
duction in cAMP signalling in affected patients. Further-
more, it has been shown that a deregulation in cAMP
signalling plays a role in the pathology of other neurode-
generative diseases such as major depressive disorder
(MDD) [52], multiple sclerosis (MS) [53] and striatal
motor disorders like Parkinson’s disease (PD) and
Huntington’s disease (HD) [54]. With regard to the use of
cAMP as a biomarker of neurodegenerative disease, and
AD in particular, different studies were conducted with
contradictory findings. For PD, some groups found a
decrease in cAMP levels [55, 56] and others showed no
statistically significant difference [57, 58]. Oeckl et al. [57]
reported a significant decrease of cAMP levels in the CSF
of Creutzfeldt-Jakob disease (CJD) patients compared with
controls. Two studies specifically investigated the CSF
levels of cAMP of AD patients. Martínez et al. [15] found
elevated cAMP CSF levels in patients suffering from AD
compared with non-demented controls. In contrast to
these results, a recently published study reported no
changes in cAMP levels in the CSF of AD patients
compared with non-demented controls [14]. In line with
the second study, we did not find statistically significant
changes in cAMP levels in the CSF of AD patients
compared with our control cohort. These results confirm
that cAMP may not be used as a marker of disease
progression and severity in AD patients.
Similarly to cAMP, the cyclic nucleotide cGMP is also
strongly linked to memory processes and is thought to
be altered in AD pathology [41]. However, compared
with cAMP, fewer studies determined changes in cGMP
signalling in AD patients. To the best of our knowledge
there are no published data determining cGMP levels in
Fig. 4 AD patients with current depression show a decrease in CSF levels of cGMP and significantly lower MMSE scores. a CSF concentration of
cGMP is decreased in AD patients suffering from current depression compared with non-depressed AD patients (p = 0.07, Mann–Whitney U test).
b AD patients with current depression show significantly lower MMSE scores (p = 0.03, Mann–Whitney U test). AD Alzheimer’s disease, cGMP cyclic
guanosine-3',5'-monophosphate, depr. depression, MMSE mini-mental state examination
Fig. 5 Exhaustive evaluation of marker combinations in a depressive subgroup. Top: cross-validation performances of all tested parameter combinations:
left, models with higher mean of sensitivity and specificity; right, models with lower performance. Bottom: corresponding parameter combinations: coloured
rectangle, corresponding parameter is used in the model; white rectangle, corresponding parameter is not used. The different parameters are ranked
according to their frequency in the top models. In the top-performing models, “cGMP” is used most frequently followed by “Albumin” and “AgeAtLP”.
AD Alzheimer’s disease, cAMP cyclic adenosine-3',5'-monophosphate, cGMP cyclic guanosine-3',5'-monophosphate (Colour figure online)
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the human brain directly. This could be due to stability
problems of cyclic nucleotides in post-mortem tissue.
Ugarte et al. [14] found increased PDE5A (cGMP degrad-
ing) expression in AD brains in a cohort of eight controls
and seven AD cases, potentially indicating decreased
cGMP in these AD brains. Furthermore, Reyes-Irisarri et
al. [59] determined the expression of cGMP-specific PDE2
and PDE9 in control and AD brains. Their study showed
no PDE5 mRNA expression in the human brain and no
changes in PDE2 or PDE9 expression, when comparing
AD patients and controls. The differences in results of
both studies could be explained by using different
methods (real-time PCR vs in-situ hybridization) or too
small a number of brain samples to conclude physiological
consequences for AD pathology. Regarding transgenic AD
rodent models, Jin et al. [60] were able to show that treat-
ment with a PDE5 inhibitor resulted in increased cGMP
levels in the cortex and hippocampus and improved learn-
ing and memory functions in APP/PS1 transgenic mice.
Furthermore, Cuadrado-Tejedor et al. [61] demonstrated
that the PDE5 inhibitor sildenafil reversed cognitive defi-
cits in Tg2576 mice compared with age-matched litter
mates. Using APP/PS1 transgenic mice, Puzzo et al. [62]
showed that PDE5 inhibition improves synaptic function
and memory in these mice. All three of these studies sup-
port an important role of cGMP in AD pathophysiology
with or without modification of brain amyloid burden.
More striking evidence for a crucial contribution of cGMP
signalling is provided by studies analysing the effects of
PDE9 inhibition in AD transgenic mice. For example, Kro-
ker et al. [9] demonstrated recently that a PDE9A inhibi-
tor is capable of restoring Aβ42 oligomer-impaired LTP in
rat hippocampal slices. They further showed that PDE9A
inhibitor treatment of Tg2576 mice enhanced cGMP
levels in the hippocampus and resulted in improved
memory performance of these mice. PDE2 can hydrolyse
both cAMP and cGMP. Sierksma et al. [63] showed that
inhibition of PDE2 improves impaired memory in the
APPswe/PS1dE9 mouse model. Nevertheless, further
studies are needed to answer the question of whether
potentially altered PDE expression in brains of AD
patients is causative for or a consequence of the disease.
Most of the aforementioned studies determining CSF
cAMP levels also analysed the levels of cGMP in the CSF
of patients suffering from a neurodegenerative disease
compared with controls. These findings were also conflict-
ing. Oeckl et al. [57] showed a significant decrease in the
CSF cGMP levels of CJD patients, but not PD or ALS
patients. In line with these findings, two other studies did
not find any differences in the CSF cGMP levels of PD
patients [56] or PD and ALS patients [64]. In contrast to
this, Belmaker et al. [55] found a significant decrease of
cGMP in PD patients. However, dementia was not deter-
mined in any of the PD studies. Martínez et al. [15] and
Ugarte et al. [14] had been the only groups to analyse
cGMP levels in the CSF of AD patients until now. While
the former study did not show statistically significant dif-
ferences in the cGMP levels of AD patients, Ugarte et al.
report a decrease of cGMP levels in mild AD patients
(MMSE 22.3 ± 0.7) compared with different controls. We
found in our study a reduction of about 40% in cGMP
levels in the CSF of AD patients compared with the
control group. Our results revealed a significant correl-
ation of CSF cGMP levels with the cognitive performance
(MMSE score) of all patients. Therefore we stratified the
AD patients by their MMSE scores into three clusters
(severe AD, moderate AD, mild AD). This showed that
the observed decrease in AD patients is mainly driven by
more severely affected patients with an MMSE score of
between 5 and 17 points. Because disturbed intracellular
mechanisms are thought to occur decades before the ap-
pearance of clinical symptoms, cGMP levels may at least
not be an early indicator for intracellular changes in AD
brains. Intracellular cGMP levels are tightly regulated and
kept on a physiological concentration by three mecha-
nisms, namely synthesis via guanylyl cyclases, degradation
via PDEs and excretion by transport proteins. Therefore,
altered pathological levels may not be observed before
synapses and neurons are degenerating. Intracellular com-
pensating mechanisms (GCs, PDEs) may counterbalance
subtle changes in cGMP levels in preclinical and pro-
dromal AD. Taken together, these results provide further
evidence for an involvement of cGMP/NO-dependent
pathways in AD pathology. The ELISA kits used by Martí-
nez et al. [15] to determine cAMP and cGMP levels in
CSF differed from ours. However, the main drawback of
their study is the use of headache patients as a control
group and the lack of neuropsychological tests for control
subjects. These facts might, at least in part, explain the
contradictory findings. Nevertheless, this should be taken
into consideration in future study designs, because head-
ache patients are commonly used as controls in neuro-
logical examinations and the involvement of cGMP/NO-
dependent pathways in cephalalgia onset is discussed in
the neurological community [65–68].
The fact that only cGMP and not cAMP levels are
decreased in the CSF of AD patients in our study might be
explained by an increased activity of cGMP-specific PDEs
in the CNS of AD patients [41]. Another explanation could
be a reduction of guanylyl cyclase activity in AD brains [11,
69]. Given that there is a massive neuron loss in AD brains
and we report a negative correlation of CSF cGMP with
CSF tau, a reduction in guanylyl cyclase activity seems to
be more likely than increased activity of PDEs. An alter-
ation in cGMP efflux to the extracellular space by specific
transporters might also be a possibility [70]. Potential age-
dependent differences in CSF cyclic nucleotide levels might
not be a relevant explanation, because we and others
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showed that levels of cyclic nucleotides do not alter with
aging (data not shown) [71]. Different measurement
values due to freezing/thawing cycles can also be ruled
out, because no stability problems with cyclic nucleo-
tides were observed [57]. Moreover, levels of cyclic
nucleotides were reported not to be subject to changes
in circadian rhythm [71].
Deeper understanding of the underlying pathophysiology
of AD and accompanying NPSs is crucial, because symptoms
such as late-life depression are highly prevalent and lead to
poor medical and functional outcomes. Because late-life de-
pression can be both a risk factor for and consequence of
AD, we subgrouped the AD cohort into AD cases with
current depression and AD patients without current depres-
sion. We found that cGMP levels are reduced in AD patients
suffering from current depression compared with non-
depressed AD patients, indicating a relationship between the
glutamatergic system and NPSs. We were also able to dem-
onstrate significantly lower MMSE scores in depressed AD
patients. The glutamatergic system is the molecular correlate
of cognitive function, and lower MMSE scores in AD pa-
tients suffering from late-life depression are also in line with
an involvement of the glutamatergic system in depressive
syndromes. Increasing evidence supports the involvement of
the glutamatergic system, including neuroplasticity, in the
pathophysiology of MDD. In mice, stress can reduce den-
dritic complexity in the CA3 region of the hippocampus,
which could be reverted by serotonin reuptake inhibitors
[72]. Further, structural imaging revealed hippocampal
atrophy in MDD patients [73, 74]. An increase of cholinergic
activity is also described to be involved in pathophysiology of
MDD [75]. Interestingly, cGMP is discussed to be a second
messenger in acetylcholine signalling [76]. Given that cholin-
ergic signalling is discussed to be enhanced in depression but
decreased in AD brains [77, 78], impaired acetylcholine ac-
tion as a common mechanism explaining our findings seems
to be unlikely. NPSs could either be a psychological reaction
to experienced cognitive decline or a risk factor for AD by
affecting the brain (e.g. by activating the neuroendocrine
axis) [79]. Whether the reduction in cGMP levels is causative
or a consequence of NPSs, such as late-life depression, is still
not known. Understanding these symptoms in more detail is
crucial, because their phenotype can help to characterize the
involved circuitries and neural regions, and thereby offer
clues about AD pathogenesis.
cGMP levels depicted only moderate discrimination
power in ROC analyses in our cohort. This may indicate
that cGMP alone is not a useful biomarker in clinical
routine, but can help in understanding the pathophysio-
logical background of AD and other neurodegenerative
diseases related to synaptic plasticity deficits. The power of
prediction could be increased when analysing cGMP levels
in CSF together with other markers. Nevertheless, levels of
cGMP in CSF might serve as a valuable marker for
monitoring target engagement of PDE inhibitors in clinical
trials, disease progression or possibly therapeutic efficacy,
because such inhibitors are considered to have high poten-
tial as future treatment options against cognitive decline in
AD patients [80, 81]. However, their therapeutic potential
for AD patients with or without NPSs still needs to be
shown in clinical trials. Nonetheless, as regards the meas-
urement of cGMP in CSF, it is of great importance to im-
prove standardization in the study design, inclusion criteria,
choice of suitable control group, sample storage and hand-
ling, and choice of assays. The strengths of the current
study are the sample size and the use of both clinical and
CSF biomarker data as diagnostic criteria, as well as the
exclusion of headache co-morbidity as a potential con-
founder and the detailed clinical characterization of the AD
group. One advantage of commercial ELISA kits compared
with other methods such as LC-MS/MS is their potential
for standardization and their usability in clinical routine
among different laboratories. Because we were able to show
that only severely demented AD patients and AD patients
suffering from current depression exhibit decreased CSF
cGMP levels, one has to be aware of the degree of cognitive
impairment and potential co-morbidities, such as depres-
sive syndromes, of patients when assembling cohorts. The
inclusion criteria should be considered carefully, making
the obtained data more reliable and comparable.
Conclusions
The present study provides further evidence for a specific
involvement of cGMP in AD pathogenesis and accompany-
ing co-morbidities, such as NPSs. We found that cGMP
shows moderate discrimination for clinical routine. Our
data provide additional support from human material for
deciphering the pathophysiological background of AD
related to synaptic dysfunction. Understanding associated
neuropsychological symptoms in the etiopathology of
neurodegenerative diseases in more detail is essential,
because their phenotype might help to delineate the
involved neural regions and circuitries and thereby offer
clues about pathogenesis of neurodegenerative diseases.
Additional file
Additional file 1: Figure S1. is showing cGMP and cAMP levels in CSF
of subjects taking antidepressants compared with subjects not taking
antidepressants separated into control and AD groups. A CSF cGMP levels
were not altered in control subjects taking antidepressants compared with
controls who did not take antidepressants (p= 0.79). B CSF cAMP levels were
not altered in control subjects taking antidepressants compared with controls
who did not take antidepressants (p= 0.51). C CSF cGMP levels were not
altered in AD patients taking antidepressants compared with AD patients who
did not take antidepressants (p= 0.60). D CSF cAMP levels were not altered in
AD patients taking antidepressants compared with AD patients who did not
take antidepressants (p= 0.38). Dark horizontal lines, mean of observed data;
box, 25th and 75th percentiles; whiskers, 5th and 95th percentiles; dots, outliers.
p values calculated using the Mann–Whitney rank-sum test. (TIF 514 kb)
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